Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $93.27 USD
Change Today -0.81 / -0.86%
Volume 997.8K
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

endo international plc (ENDP) Key Developments

Endo International Launches Nasal Gel Testosterone Treatment

Endo International (ENDP) announced that it launched Natesto. The company noted the nasal gel was approved by the Food and Drug Administration in May 2014 for adult men with deficiency or absence of endogenous testosterone, including conditions both congenital or acquired. Endo also makes and sells other testosterone gels and implantable testosterone pellets, but it said the nasal gel reduces the risk of transference via intranasal application. The company said it obtained rights to the nasal gel for sale in the U.S. and Mexico from Trimel Pharmaceuticals for $25 million, plus additional payments related to regulatory and sales milestones.

Endo International Mulls Acquisition

Endo International plc (NasdaqGS:ENDP) is seeking acquisition. ''While we are disappointed with this outcome, we have been and will continue to be disciplined in our approach to potential acquisitions,'' Endo said in a statement, adding that it will focus on other acquisition opportunities and organic growth. ''We would like to wish Salix and Valeant continued success as they move forward with their transaction,'' Endo International said.

Endo International plc Presents at Barclays Global Healthcare Conference, Mar-12-2015 02:05 PM

Endo International plc Presents at Barclays Global Healthcare Conference, Mar-12-2015 02:05 PM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Rajiv Kanishka Liyanaarchchie De Silva, Chief Executive Officer, President and Director.

Endo International plc Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for Fiscal 2015

Endo International plc reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. The company reported revenue of $799,957,000, operating loss of $72,668,000, loss from continuing operations before income tax of $119,917,000, net loss attributable to company of $53,483,000 or $0.35 per diluted share against revenue of $584,946,000, operating loss of $732,481,000, loss from continuing operations before income tax of $775,061,000, net loss attributable to company of $775,910,000 or $6.74 per diluted share a year ago. Non-GAAP net income was $184,884,000 or $1.16 per diluted share against $123,697,000 or $0.96 per diluted share a year ago. The decrease in net sales is primarily attributable to a year-over-year decrease in demand due to generic competition. For the year, the company reported revenue of $2,877,188,000, operating loss of $896,943,000, loss from continuing operations before income tax of $1,125,701,000, net loss attributable to company of $721,319,000 or $4.91 per diluted share against revenue of $2,616,907,000, operating loss of $425,625,000, loss from continuing operations before income tax of $559,567,000, net loss attributable to company of $685,339,000 or $6.05 per diluted share a year ago. Net cash provided by operating activities was $337,776,000 against $298,517,000 a year ago, Purchases of property, plant and equipment was $80,251,000 against $94,626,000 a year ago. Non-GAAP net income was $674,898,000 or $4.31 per diluted share against $573,996,000 or $4.79 per diluted share a year ago. For the full twelve months ended December 31, 2015, at current exchange rates, the company estimates total revenue to be between $2.90 billion and $3.00 billion. Reported (GAAP) diluted EPS from continuing operations to be between $2.73 and $2.93. Adjusted diluted earnings per share from continuing operations to be between $4.35 and $4.55. Adjusted diluted earnings per share assume full year adjusted diluted shares outstanding of 180 million. The company's 2015 guidance is based on certain assumptions including: adjusted gross margin of between 63% and 65%, adjusted interest expense of approximately $310 million and adjusted effective tax rate of between 15% and 17%. The company expects corporate gross margin as a percentage of revenues to be between 63% and 65% in 2015. The company expects adjusted interest expense in 2015 of approximately $310 million. Adjusted basis, the company expects corporate gross margin as a percentage of revenues to be between 63% and 65% in 2015.

Endo International Considers Strategic Alternatives For American Medical System

Endo International plc (NasdaqGS:ENDP) is exploring various strategic alternatives for women's health business of its American Medical Systems Holdings Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $93.27 USD -0.81

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.126.90 CHF +2.90
CR Bard Inc $175.38 USD -0.87
Edwards Lifesciences Corp $138.33 USD -3.59
Intuitive Surgical Inc $505.92 USD -6.85
Mallinckrodt PLC $122.01 USD -2.84
View Industry Companies
 

Industry Analysis

ENDP

Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.0x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.